Rinvoq - Beechwood Capital

Drug Profile

ModalitySmall molecule

RouteORAL

Therapy AreaImmunology

Launch2019-08-16

US LOE2034-01-01

Peak Sales Est$12000M

Formulations[{"id":"rinvoq-po","doses":"15mg, 30mg, 45mg","route":"PO","setting":"OUTPATIENT","frequency":"Once

Companies

ABBV (ORIGINATOR)100%

Expert: Janus kinase inhibitor that blocks JAK1/JAK2 signaling, inhibiting cytokine-driven inflammatory cascades. Oral small molecule alternative to biologics for autoimmune diseases.

Everyday: Blocks signals inside immune cells that cause inflammation. Used for arthritis and other autoimmune conditions.

Targets: ["JAK"]

Period	Revenue ($M)
2024	$5,986M
2025	$8,304M
Q4 2025	$2,330M

Indication	Stage	Key Study	Regional Status
AA	PHASE3	UP-AA	[]
GCA	APPROVED	SELECT-GCA	[{"stage":"APPROVED","region":"US","approval_date":"2025-12-01"}]
HS	PHASE3	SELECT-HS	[]
Vitiligo	FILED	Viti-Up	[]
RA	APPROVED	SELECT-COMPARE, SELECT-MONOTHERAPY	[{"stage":"APPROVED","region":"US","approval_date":"2019-08-16"},{"stage":"APPRO
PsA	APPROVED	SELECT-PsA 1/2	[{"stage":"APPROVED","region":"US","approval_date":"2021-12-14"},{"stage":"APPRO
AD	APPROVED	Measure Up 1/2, AD Up	[{"stage":"APPROVED","region":"US","approval_date":"2022-01-14"},{"stage":"APPRO
UC	APPROVED	U-ACHIEVE, U-ACCOMPLISH	[{"stage":"APPROVED","region":"US","approval_date":"2022-03-16"},{"stage":"APPRO
CD	APPROVED	U-EXCEL, U-EXCEED	[{"stage":"APPROVED","region":"US","approval_date":"2023-05-19"},{"stage":"APPRO
AS	APPROVED	SELECT-AXIS 1	[{"stage":"APPROVED","region":"US","approval_date":"2022-06-06"},{"stage":"APPRO
SLE	PHASE3	SLE Ph3	[]
Crohn's Disease	APPROVED	—	[]
Crohn's Disease	APPROVED	—	[]

Rinvoq - Vitiligo - FDA Approval 2026

Rinvoq - GCA - FDA Approval 2026

Rinvoq - Alopecia Areata - Ph3 - Data (UP-AA) 2026

Rinvoq - HS - Ph3 - Data 2026

Rinvoq - SLE - Ph3 - Data 2026

Selective JAK1 inhibitor. 9 approved indications in US (RA, PsA, AD, UC, CD, AS, axSpA, nr-axSpA, GCA). 2025 revenue $8.3B (+39% YoY). Expanding into vitiligo, AA, HS, SLE.

{"keyRisks":[{"category":"Infections","description":"Serious infections, herpes zoster"},{"category":"Malignancy","description":"Lymphoma and other malignancies"},{"category":"Cardiovascular","description":"MACE, VTE/PE"},{"category":"Hepatic","description":"Hepatic disorders"},{"category":"Hematologic","description":"Neutropenia (30mg)"}],"monitoring":["CBC","LFTs","Lipids"],"labelSource":"FDA PI 2024","hasBoxedWarning":true,"boxedWarningText":"Serious infections, mortality, malignancies, MACE, VTE/PE, GI perforations","boxedWarningCategories":["Infections","Malignancy","Cardiovascular","Thrombosis"]}